Noninvasive Respiratory Support in COVID-19 (CATCOVID-AIR)

Vall d'Hebron University Hospital (HUVH)

Status: Completed

Conditions: Corona Virus Infection; Covid19; Acute Respiratory Failure

Treatments: Device: Continuous positive airway pressure (CPAP) treatment; Device: Noninvasive ventilation treatment; Device: High-flow nasal cannula treatment

Study type: Observational

Funder types: Other

Identifiers

NCT04668196

PR(AG)265/2020

Details and patient eligibility

About

COVID-19 pneumonia can cause severe acute hypoxemic respiratory failure. The usefulness of noninvasive respiratory support (NIRS), by means of nasal high-flow oxygen (NHFO), continuous positive airway pressure (CPAP), or noninvasive ventilation (NIV), established outside the intensive care unit, is unknown. The aim of this multicenter, retrospective, longitudinal study is to compare the effectiveness of these treatments to prevent death or endotracheal intubation at day 28, and what factors, related to the disease or to the characteristics of the treatment itself, can condition its success or failure.

Full description

Multicenter, retrospective, longitudinal study in consecutive adult COVID-19 patients with acute respiratory failure, requiring noninvasive respiratory support (NIRS) outside the intensive care unit (ICU) in 10 hospitals in Catalonia (Spain). Demographic, laboratory, clinical and noninvasive respiratory support data will be collected and analyzed according to the primary outcome (death or endotracheal intubation at day 28) and secondary outcomes (see the dedicated section).

During the hospitalization, patients were treated according to the standard procedures of the participating centers. This study is observational and no randomization have been performed.

Patients were followed up to either 28-days or hospital discharge if still hospitalized at day 28 from NIRS initiation.

Enrollment: 367 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• COVID-19 pneumonia confirmed with polymerase chain reaction (PCR).
• Acute respiratory failure.
• Treated by noninvasive respiratory support (nasal high-flow oxygen, CPAP or noninvasive ventilation), initiated outside the intensive care unit.
• Age > 18 years

Exclusion criteria

• Acute respiratory failure not related to COVID-19
• Hypercapnic acute respiratory failure
• Early intolerance to treatment
• Nosocomial infection
• Pregnant woman

Trial design

367 participants in 3 patient groups

High-flow nasal cannula treatment

Treatment:

Device: High-flow nasal cannula treatment

Continuous positive airway pressure (CPAP) treatment

Treatment:

Device: Continuous positive airway pressure (CPAP) treatment

Noninvasive ventilation treatment

Treatment:

Device: Noninvasive ventilation treatment